Liquid Biopsy Tests are emerging as a viable alternative to traditional methods for cancer screening. A liquid biopsy is a new type of blood test that has the potential to transform cancer treatment. Using this methodology, physicians avoid the traditional surgical and needle biopsies they use to determine the existence of cancer in patients. In United States Liquid Biopsy market; Screening Test is likely to capture major chunk of the market compared to Monitoring Market. It is anticipated that Liquid Biopsy Testing will be more helpful for monitoring cancer treatment and status after diagnosis than in screening for a cancer that may be years or even decades in the making and not otherwise detectable.
United States – Liquid Biopsy Potential Screening Market Analysis: In the United States liquid biopsy screening market, prostate cancer is the most popular segment. Lung cancer liquid biopsy screening stands at the last spot.
United States – Liquid Biopsy Potential Treatment Monitoring Market Analysis: In the United States liquid biopsy treatment monitoring market, breast cancer is the leading segment. Liver cancer stands at the fifth spot.
Renub Research report titled “United States – Liquid Biopsy Potential Testing Market & Volume Analysis to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Liquid Biopsy Market. This 79 page report with 41 Figures analyses the United States Liquid Biopsy Test Market and Volume by 5 Top Cancer Segment, Recent developments, Major Deals along with the driving factors and challenges for Liquid Biopsy Market.
The United States Liquid Biopsy Potential Market has been analyzed from two view points
1. United States Liquid Biopsy Potential Screening Market & Test Volume (2015 – 2020)
The Top 5 Cancer Segments covered are:
1.Lung Cancer
2.Breast Cancer
3.Colorectal Cancer
4.Prostate Cancer
5.Liver Cancer
2. United States Liquid Biopsy Potential Treatment Monitoring Market & Test Volume (2015 – 2020)
The Top 6 Cancer Segments covered are:
1.Lung Cancer
2.Breast Cancer
3.Colorectal Cancer
4.Prostate Cancer
5.Liver Cancer
6.Other Cancers
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary research and in–house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non–printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.
Click here to view the report details: http://www.renub.com/united-states-liquid-biopsy-potential-testing-market-and-volume-analysis-to-2020-515-p.php
For more information:
Contact Us
Rajat Gupta
Sr. Manager
Sales & Marketing Div
Renub Research
Email: info@renub.com
Phone: Phone: +1-678-302-0700 (USA), +91-120-421-9822, +91-120-424-9780 (India)
Web: http://www.renub.com
Follow us:
https://www.facebook.com/RenubResearch/
https://twitter.com/renubresearch
https://www.linkedin.com/company/renub-research
.jpg)
